Scarica l'app Stockscreener
335.16
4.23%
-14.81
Pre-mercato:
310.01
-25.15
-7.50%
Precedente Chiudi:
$349.97
Aprire:
$349.44
Volume 24 ore:
251.06K
Relative Volume:
0.64
Capitalizzazione di mercato:
$9.34B
Reddito:
$7.46M
Utile/perdita netta:
$-303.27M
Rapporto P/E:
-24.89
EPS:
-13.4668
Flusso di cassa netto:
$-249.12M
1 W Prestazione:
-2.44%
1M Prestazione:
+3.38%
6M Prestazione:
+81.60%
1 anno Prestazione:
+769.42%
Intervallo 1D:
$332.18
$349.44
Intervallo di 1 settimana:
$332.18
$366.52
Portata 52W:
$37.19
$366.52
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Nome
Praxis Precision Medicines Inc
Settore
Industria
Telefono
617-300-8460
Indirizzo
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
335.16 | 9.76B | 7.46M | -303.27M | -249.12M | -13.47 |
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.59B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
600.66 | 64.45B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
836.09 | 51.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.63 | 40.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
163.68 | 33.48B | 742.00K | -1.37B | -1.07B | -7.0731 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Iniziato | Raymond James | Strong Buy |
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-02-02 | Iniziato | Wells Fargo | Equal Weight |
| 2025-12-15 | Reiterato | Oppenheimer | Outperform |
| 2025-11-19 | Iniziato | BTIG Research | Buy |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-03 | Reiterato | H.C. Wainwright | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-08-05 | Iniziato | Oppenheimer | Outperform |
| 2024-06-24 | Iniziato | Needham | Buy |
| 2024-06-18 | Iniziato | Guggenheim | Buy |
| 2024-05-01 | Iniziato | Robert W. Baird | Outperform |
| 2023-09-19 | Iniziato | Truist | Buy |
| 2022-06-06 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2021-08-26 | Iniziato | BofA Securities | Buy |
| 2021-04-26 | Iniziato | William Blair | Outperform |
| 2020-11-11 | Iniziato | Wedbush | Outperform |
| 2020-11-10 | Iniziato | Cowen | Outperform |
| 2020-11-10 | Iniziato | Evercore ISI | Outperform |
| 2020-11-10 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Praxis Precision Medicines Inc Borsa (PRAX) Ultime notizie
PRAX Stock Drops 12% After Hours On Trial Setback — Retail Eyes FDA Approval Of Other Pipeline Candidates - TradingView
Praxis Precision (PRAX) Sees 15% Drop After POWER1 Study Update - GuruFocus
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Praxis Precision Medicines, Inc. announces that its clinical trial has met a key secondary endpoint with a 50% response rate. - Bitget
According to documents submitted to the U.S. Securities and Exchange Commission (SEC), National Health Investors announced on May 26, 2026, that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) for its facility sale tran - Bitget
Praxis Precision Medicines announced that its drug Vormatrigine demonstrated good tolerability in clinical trials. - Bitget
Praxis Precision Medicines reports Phase 2/3 study results for vormatrigine in epilepsy - Investing.com
Praxis reports phase 2/3 epilepsy trial missed primary endpoint By Investing.com - Investing.com India
Praxis (NASDAQ: PRAX) vormatrigine focal seizure study misses main goal but shows signals - Stock Titan
Praxis pauses vormatrigine enrollment after study misses main goal - Stock Titan
FDA Acceptance of Two CNS NDAs Might Change The Case For Investing In Praxis Precision Medicines (PRAX) - Yahoo Finance
Truist Securities maintains Praxis Precision Medicines (PRAX) buy recommendation - MSN
Praxis Precision Medicines (PRAX): Best Mid Cap Stocks to Buy with Highest Upside Potential - Insider Monkey
Trading the Move, Not the Narrative: (PRAX) Edition - Stock Traders Daily
Guggenheim Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $800 - Moomoo
Praxis Precision Medicines stock hits 52-week high at 360.8 USD - Investing.com Canada
10 Best Mid Cap Stocks to Buy with Highest Upside Potential - Insider Monkey
Praxis Precision Medicines stock hits 52-week high at 360.8 USD By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,245 - Moomoo
PRAX Technical Analysis | Trend, Signals & Chart Patterns | PRAXIS PRECISION MEDICINES I (NASDAQ:PRAX) - ChartMill
symbol__ Stock Quote Price and Forecast - CNN
PRAX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $1245 - GuruFocus
H.C. Wainwright reiterates Praxis Precision stock rating on patent news By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Praxis Precision stock rating on patent news - Investing.com
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $795 - Moomoo
PRAX Reiterated by BTIG -- Price Target Maintained at $843.00 - GuruFocus
Praxis (NASDAQ: PRAX) COO adds shares through Employee Stock Purchase Plan - Stock Titan
Praxis (NASDAQ: PRAX) accounting officer adds shares through employee stock purchase plan - Stock Titan
Praxis (PRAX) CEO acquires 126 ESPP shares as compensation - Stock Titan
Praxis Precision’s tremor-drug trial succeeds where others have failed. The stock is skyrocketing. - MSN
HighVista Strategies Sells 69,092 Shares of Structure Therapeutics in Q1 2026News and Statistics - IndexBox
Is FDA NDA Progress Amid Wider Losses Altering The Investment Case For Praxis Precision Medicines (PRAX)? - Yahoo Finance
Needham Reiterates Praxis Precision Medicines (PRAX) Buy Recommendation - MSN
(PRAX) Volatility Zones as Tactical Triggers - Stock Traders Daily
[SCHEDULE 13G] Praxis Precision Medicines, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Point72 entities and Cohen report 0.2% stake in Praxis (PRAX) - Stock Titan
Orbis and Allan Gray report 8.9% stake in Praxis Precision Medicines (PRAX) - Stock Titan
Guggenheim Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - MSN
Praxis Precision Medicines stock (US74006W1036): Biotech innovator in CNS disorders - AD HOC NEWS
Praxis Precision Medicines stock hits 52-week high at $358.01 By Investing.com - Investing.com South Africa
Praxis Highlights FDA NDA Acceptances and Strengthened Cash Runway - TipRanks
Praxis (PRAX) widens Q1 2026 loss while advancing four late-stage CNS drugs - Stock Titan
Praxis Precision Medicines stock hits 52-week high at $358.01 - Investing.com India
Praxis Precision Medicines (NASDAQ:PRAX) Given New $715.00 Price Target at Truist Financial - MarketBeat
Truist Financial Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $715 - Moomoo
HC Wainwright Issues Pessimistic Outlook for PRAX Earnings - MarketBeat
Lifesci Capital Brokers Lower Earnings Estimates for PRAX - MarketBeat
PRAX Stock Price, Quote & Chart | PRAXIS PRECISION MEDICINES I (NASDAQ:PRAX) - ChartMill
Praxis Precision Medicines Maps High-Stakes Launch Path - TipRanks
Wedbush Maintained an Underperform Rating on Praxis Precision Medicines, Inc. (PRAX) - Yahoo Finance
UBS Group AG Sells 7,612 Shares of Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines Inc Azioni (PRAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.00%
3.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):